Isotiorga

Isotretinoin, the active ingredient in Isotiorga, is a retinoid presented as an oral formulation for oral use. It is indicated for severe nodular acne and recalcitrant acne vulgaris in patients who have not responded to conventional therapies.

GNH USA supplies Isotiorga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isotiorga is a retinoid that targets severe forms of acne by modulating sebaceous gland activity and inflammation. - Severe nodular acne: reduces lesion count and prevents new nodule formation. - Recalcitrant acne vulgaris: improves skin clearance when standard treatments fail. - Acne resistant to other therapies: provides long‑term remission in difficult‑to‑treat cases.

Isotiorga may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry skin and mucous membranes. - Cheilitis (cracked lips). - Photosensitivity. - Mild headache. - Transient elevation of liver enzymes. - Hypertriglyceridemia.

Serious or Rare Side Effects: - Severe depression or mood changes. - Inflammatory bowel disease. - Pancreatitis. - Significant liver injury. - Teratogenic effects (birth defects). - Pseudotumor cerebri (increased intracranial pressure).

Isotiorga requires careful monitoring and specific safety measures before and during therapy. - Pregnancy contraindicated: avoid use in pregnant women. - Women of childbearing potential: use effective contraception throughout treatment and for one month after discontinuation. - Monitor liver function tests regularly. - Monitor lipid profile and triglyceride levels. - Avoid concurrent vitamin A supplementation. - Store at below 25°C: keep in the original pack, protect from moisture.

Isotiorga can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive toxicity. - Systemic corticosteroids: heightened risk of pseudotumor cerebri.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduced contraceptive effectiveness. - Enzyme‑inducing anticonvulsants: may lower isotretinoin plasma levels. - Statins (lipid‑lowering agents): increased risk of muscle toxicity.